General Information of Drug (ID: DMYXOU2)

Drug Name
NRX-4204 Drug Info
Synonyms
AGN-190205; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 2 [1]
Cross-matching ID
PubChem CID
9863342
TTD Drug ID
DMYXOU2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [3]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [4]
IRX4204 DM9SCME Breast cancer 2C60-2C65 Phase 1 [5]
9cUAB-30 DMYKPXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
SR-11237 DMQG3CK Solid tumour/cancer 2A00-2F9Z Terminated [7]
AGN-34 DM5ECDM Discovery agent N.A. Investigative [8]
LG100754 DMEK4FY Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid receptor RXR-gamma (RXRG) TTH029C RXRG_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2811).
2 DOI: 10.1038/scibx.2010.766
3 Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
4 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
5 Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79.
6 In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
7 Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem. 2009 Jul;4(7):1143-52.
8 Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
9 Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3.